EUCTR2007-004645-15-IT进行中（未招募）1 期
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia - ND
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 142
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •. Children of either sex and of any race, 3 months to <18 years of age. 2. Subjects must have documented or anticipated neutropenia (ANC <500/mm3 [0.5 x 109/L]) expected to last for at least 7 days and only in the following clinical situations: Acute leukemia (including new and relapse), Myelodysplasia, Severe aplastic anemia, Autologous HSCT recipients, High risk neuroblastoma, Advanced stage non-Hodgkin?s lymphoma
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Subjects with proven IFI, as defined by the MSG/EORTC criteria prior to study entry. 2. Subjects with Grade 3 or Grade 4 nausea and/or vomiting at Screening. 3. Subjects receiving weekly vincristine. 4. Subjects receiving systemic antifungal other than POS (oral, non-absorbable antifungals are permitted). 5. Subjects who have received POS within the past 10 days prior to Screening. 6. Subjects receiving or planning to receive prohibited drugs during POS administration (please refer to Table 3). 7. Subjects whose laboratory tests are outside normal limits, as follows: a. AST or ALT >5 times the upper limit of normal (ULN) b. Serum total bilirubin >2.5 x ULN c. Calculated creatinine clearance <30 mL/min. Creatinine clearance will be calculated using the following equation: Creatinine clearance = k*height (cm)/serum creatinine (mg/dL) Where k = 0.45 for a full term baby less than 1 year old; 0.55 for children up to 12 years old; 0.55 for females between the ages of 13 and 21 years; 0.7 for males between the ages of 13 and 21 years. 8. Subjects with QTc prolongation: a. Symptomatic QTc prolongation >450 msec (males) or >470 msec (females) b. Any QTc prolongation of >500 msec 9. Subjects who are unable to receive study drug enterally. 10. Female subjects who are pregnant, intend to become pregnant during the course of the study, or are breast-feeding. 11. Subjects with a history of anaphylaxis attributed to the azole class of antifungal agents. 12. Subjects with any clinically significant condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with the study evaluations or optimal participation in the study, including receiving less than 7 days of POS. 13. Subjects who have already participated in this study or are participating in any Phase 1 clinical study or any study for a medication that has not yet received regulatory approval. 14. Subjects who are part of the study staff personnel or family members of the study staff personnel
研究者
相似试验
进行中（未招募）
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropeniaTreatment and prophylaxis of invasive fungal infectionsoropharyngeal candidiasis (OPC) and refractory OPC.MedDRA version: 17.1Level: PTClassification code 10050346Term: Oropharyngeal candidiasisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2007-004645-15-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.108
已完成
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropenialeukemiaNL-OMON39331Merck Sharp & Dohme (MSD)23
进行中（未招募）
不适用
A study to look at safety and acceptance of Posaconazole (study drug) given by mouth to children with a blood illness.Treatment and prophylaxis of invasive fungal infectionsMedDRA version: 14.1Level: LLTClassification code 10062642Term: Invasive mycosisSystem Organ Class: 100000004862EUCTR2007-004645-15-GRSchering Plough Research Institute, A Division of Schering Corporation108
进行中（未招募）
不适用
Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With NeutropeniaEUCTR2007-004645-15-NLSchering Plough Research Institute, A Division of Schering Corporation108
未知
1 期
Phase 1 Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant TumorsJPRN-jRCT2080223015Bristol-Myers Squibb K.K.18